share_log

Reported Wednesday, HUTCHMED Divests 45% Stake In Shanghai Hutchison Pharmaceuticals For $608M To Focus On Core R&D And Innovative Oncology Therapies

Benzinga ·  Jan 1 22:11
  • HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —
  • Divestment proceeds to advance HUTCHMED's pipeline and core innovative medicines business —
  • Focused R&D investment includes HUTCHMED's proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 —
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment